• Home
  • Search Results
  • Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs.

Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs.

Molecular pharmaceutics (2015-01-24)
Jie Wang, Vipul Yadav, Alice L Smart, Shinichiro Tajiri, Abdul W Basit

A major barrier to successful oral delivery of peptide and protein molecules is their inherent instability in the lumen of the gastrointestinal tract. The aim of this study was to determine the stability of 17 disparate peptide drugs (insulin, calcitonin, glucagon, secretin, somatostatin, desmopressin, oxytocin, [Arg(8)]-vasopressin, octreotide, ciclosporin, leuprolide, nafarelin, buserelin, histrelin, [d-Ser](4)-gonadorelin, deslorelin, and goserelin) in gastric and small intestinal fluids from both humans and pigs, and in simulated gastric and intestinal fluids. In human gastric fluid, the larger peptides including somatostatin, calcitonin, secretin, glucagon, and insulin were metabolized rapidly, while the smaller peptides showed good stability. In human small intestinal fluid, however, both small and large peptides degraded rapidly with the exception of the cyclic peptide ciclosporin and the disulfide-bridge containing peptides octreotide and desmopressin, which showed good stability. The stability of peptides in both simulated gastric fluid and pig gastric fluid correlated well with stability in human gastric fluid. However, it was not possible to establish such a correlation with the small intestinal fluids because of the rapid rate of peptide degradation. This work has identified the molecular features in the structure of a wide range of peptides that influence their stability in the environment of the gastrointestinal tract, which in turn will allow for better selection of peptide candidates for oral delivery.

Product Number
Product Description

Trifluoroacetic acid, suitable for HPLC, ≥99.0%
Trifluoroacetic acid, ReagentPlus®, 99%
Trifluoroacetic acid, puriss. p.a., suitable for HPLC, ≥99.0% (GC)
Trifluoroacetic acid, ≥99%, for protein sequencing
Trifluoroacetic acid, analytical standard
Oxytocin, lyophilized powder, ~15 IU/mg solid (Prepared from synthetic oxytocin)
Octreotide, ≥98% (HPLC)
Sodium trichloroacetate, 97%
Oxytocin, European Pharmacopoeia (EP) Reference Standard
Oxytocin, United States Pharmacopeia (USP) Reference Standard
Desmopressin, European Pharmacopoeia (EP) Reference Standard
Goserelin acetate, ≥99% (HPLC), white powder
Goserelin, European Pharmacopoeia (EP) Reference Standard
[des-Gly10, D-His(Bzl)6]-LH-RH ethylamide, ≥97% (HPLC), powder
Goserelin for NMR identification, European Pharmacopoeia (EP) Reference Standard

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.